首页> Journal of cancer research and clinical oncology> Sclerosing mesenteritis following immune checkpoint inhibitor therapy.

Sclerosing mesenteritis following immune checkpoint inhibitor therapy.

导出 OA

翻译打印收藏纠错

第一作者： Andrew G,Kuang

第一单位： Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

作者： Andrew G,Kuang ^[1] ; Gabriel,Sperling ^[2] ; Tom Z,Liang ^[3] ; Yang,Lu ^[4] ; Dongfeng,Tan ^[3] ; Kathryn,Bollin ^[5] ; Douglas B,Johnson ^[6] ; Joanna-Grace M,Manzano ^[7] ; Malek,Shatila ^[8] ; Anusha S,Thomas ^[8] ; John A,Thompson ^[9] ; Hao Chi,Zhang ^[8] ; Yinghong,Wang ^[10]

作者单位： Department of Medicine, Baylor College of Medicine, Houston, TX, USA. ^[1] The University of Texas Medical Branch John Sealy School of Medicine, Galveston, TX, USA. ^[2] Division of Pathology/Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[3] Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[4] Division of Hematology and Oncology, Scripps MD Anderson Cancer Center, La Jolla, CA, USA. ^[5] Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. ^[6] Department of Hospital Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[7] Department of Gastroenterology, Hepatology, & Nutrition, Division of Internal Medicine, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. ^[8] Divison of Medical Oncology, University of Washington, Seattle, WA, USA. ^[9] Department of Gastroenterology, Hepatology, & Nutrition, Division of Internal Medicine, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. ywang59@mdanderson.org. ^[10]

关键词 Anti-CTLA-4 Anti-PD-1/L1 Immune checkpoint inhibitor Immune-related adverse event Sclerosing mesenteritis